HYL.BR BRU
Hyloris Pharmaceuticals S.A.
1W: -5.6%
1M: -6.5%
3M: -4.1%
YTD: -43.4%
1Y: -35.4%
3Y: -64.0%
5Y: -68.4%
€4.20 ($4.69)
-0.05 (-1.18%)
Weekly Expected Move ±5.8%
€4
€4
€4
€4
€5
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Cash Flow Trends
Operating Cash Flow
-$7M
+1.6% ▲
Capital Expenditures
$4K
+86.2% ▲
5Y CAGR: -63.6%
Free Cash Flow
-$7M
+2.0% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$10M
-44.1% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$12M | -$11M | -$15M | -$6M | -$6M |
| Depreciation & Amort. | $137K | $196K | $348K | $1M | $919K |
| Stock-Based Comp. | $576K | $560K | $540K | -$540K | $0 |
| Change in Working Capital | -$777K | -$3M | $2M | -$1M | -$691K |
| Other Non-Cash Items | $197K | $235K | -$256K | $228K | -$489K |
| Operating Cash Flow | -$11M | -$13M | -$13M | -$7M | -$7M |
| — Investing Activities — | |||||
| Capital Expenditures | -$1M | -$739K | -$298K | -$29K | -$629K |
| Acquisitions (Net) | -$1M | $0 | $0 | $0 | $0 |
| Investment Purchases | -$1M | -$500K | $0 | $0 | -$2M |
| Investment Sales | $216K | $522K | $10M | $0 | $0 |
| Other Investing | $218K | -$522K | $187K | $288K | $0 |
| Investing Cash Flow | -$3M | -$1M | $10M | $259K | -$3M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$62K | -$7M | $51K | -$168K | $0 |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | $0 | -$2M | -$182K | -$200K | -$431K |
| Financing Cash Flow | -$62K | $8M | -$131K | -$368K | -$431K |
| Net Change in Cash | -$14M | -$7M | -$3M | -$7M | -$10M |
| Cash End of Period | $50M | $43M | $30M | $24M | $14M |
| Free Cash Flow | -$12M | -$14M | -$13M | -$7M | -$7M |